Citations

Showing 10 of 108135 citations.

Clinicoradiographic and genetic features of cerebral small vessel disease indicate variability in mode of inheritance for monoallelic HTRA1 variants
Muthusamy, Karthik , Klee, Eric W. , Wierenga, Klaas J. , Gavrilova, Ralitza H. , Muthusamy, Karthik , Ferrer, Alejandro

Mayo Clinic

Molecular Genetics & Genomic Medicine | September 12, 2021 | Volume: 9 | Issue: 10 | Pages: No page available

10.1002/mgg3.1799 | PMID 34510819 Get It

AbstractBackgroundBiallelic pathogenic variants in HTRA1 cause CARASIL. More recently, monoallelic variants have been associated with the autosomal dominant disorder CADASIL2 but not all carriers develop disease manifestations. We describe the clinicoradiologic and mutation spectrum of four new CADASIL2 individuals.MethodsMedical records at Mayo Clinic between 2013 and 2020 were retrospectively reviewed to identify patients with cerebral small vessel disease related to monoallelic HTRA1 variants.ResultsFour patients met the study inclusion criteria for cerebral small vessel disease related to HTRA1 monoallelic variants. The mean age at onset of first clinical stroke was 51.25 years (range 41–64 years). The mean disease duration was 6.5 years (range 4–12). All individuals had recurrent strokes within the duration of follow‐up with a mean number of strokes per patient being 5.5 (range 2–12). Three individuals had leukoencephalopathy with brain stem involvement. Microhemorrhages were seen on brain MRI in three patients. HTRA1 monoallelic variants identified in our cohort were missense variants in three patients and a novel frameshift variation in one patient. Interestingly, two of these missense variants were previously reported in an autosomal recessive pattern of inheritance and here are associated with a dominant effect.ConclusionsClinicoradiologic characteristics of heterozygous HTRA1‐related CSVD may overlap with sporadic CSVD. Heterozygous HTRA1 variants can contribute to dominant or recessive disease mechanisms.
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study
Gidener, Tolga , Yin, Meng , Dierkhising, Ross , Allen, Alina M. , Ehman, Richard L. , Venkatesh, Sudhakar K. , Dierkhising, Ross A , Ehman, Richard , Venkatesh, Sudhakar K , Allen, Alina M , Yin, Meng , Gidener, Tolga

Mayo Clinic

Hepatology | September 12, 2021 | Volume: 75 | Issue: 2 | Pages: 379-390

10.1002/hep.32151 | PMID 34510513 Get It

Abstract Background and Aims Although magnetic resonance elastography (MRE) has been well‐established for detecting and staging liver fibrosis, its prognostic role in determining outcomes of chronic liver disease (CLD) is mostly unknown. Approach and Results This retrospective study consisted of 1269 subjects who underwent MRE between 2007 and 2009 and followed up until death or last known clinical encounter or end of study period. Charts were reviewed for cirrhosis development, decompensation, and transplant or death. The cohort was split into baseline noncirrhosis (group 1), compensated cirrhosis (group 2), and decompensated cirrhosis (group 3). Cox‐regression analysis with age, sex, splenomegaly, CLD etiology, Child‐Pugh Score (CPS), Fibrosis‐4 Index (FIB‐4) score, and Model for End‐Stage Liver Disease (MELD)–adjusted HR for every 1‐kPa increase in liver stiffness measurement (LSM) were used to assess the predictive performance of MRE on outcomes. Group 1 ( n = 821) had baseline median LSM of 2.8 kPa, and cirrhosis developed in 72 (8.8%) subjects with an overall rate of about 1% cirrhosis/year. Baseline LSM predicted the future cirrhosis with multivariable adjusted HR of 2.38 ( p < 0.0001) (concordance, 0.84). In group 2 ( n = 277) with baseline median LSM of 5.7 kPa, 83 (30%) subjects developed decompensation. Baseline LSM predicted the future decompensation in cirrhosis with FIB‐4 and MELD‐adjusted HR of 1.22 ( p < 0.0001) (concordance, 0.75). In group 3 ( n = 171) with median baseline LSM of 6.8 kPa (5.2, 8.4), 113 (66%) subjects had either death or transplant. Baseline LSM predicted the future transplant or death with HR of 1.11 ( p = 0.013) (concordance 0.53) but not in CPS and MELD‐adjusted models ( p = 0.08). Conclusion MRE‐based LSM is independently predictive of development of future cirrhosis and decompensation, and has predictive value in future transplant/death in patients with CLD.
Peripheral Microvascular Dysfunction is Associated with Plaque Progression and Adverse Long-Term Outcomes in Heart Transplant Patients
Toya, Takumi , Ahmad, Ali , Lerman, Lilach O. , Kushwaha, Sudhir S. , Ozcan, Ilke, Toya, Takumi , Ӧzcan, Ilke , Corban, Michel , Lerman, Amir

Mayo Clinic

ESC Heart Failure | September 12, 2021 | Volume: 8 | Issue: 6 | Pages: 5266-5274

10.1002/ehf2.13610 | PMID 34510802 Get It

Abstract Aims Cardiac allograft vasculopathy (CAV) is the major cause of increased morbidity and mortality after heart transplantation. Peripheral endothelial dysfunction (PED) is associated with early atherosclerosis and future risk of major adverse cardiovascular events (MACE) in non-heart transplant population. We aimed to investigate the association of PED with future MACE, and plaque progression assessed by intravascular ultrasound (IVUS) after heart transplantation. Methods and results We included 66 transplant patients who underwent serial IVUS surveillance for CAV and baseline assessment of peripheral endothelial function using reactive hyperaemia peripheral arterial tonometry. PED was defined as reactive hyperaemia index &lt; 2. The primary endpoint of the study was to investigate the association of PED with CAV progression assessed by intravascular ultrasound (IVUS). CAV progression was assessed as the change (Δ) in plaque volume divided by segment length, and Δ plaque index (plaque volume/vessel volume), adjusted for the time between IVUS measurements (median 3.0 [2.2, 3.1] years). The secondary endpoint was to investigate the association between PED and future MACE, which was defined as any incident of revascularization, heart failure hospitalization, stroke, myocardial infarction, re-transplantation, and death. Patients with PED (n = 27) had more yearly plaque progression (0.50 ± 0.66 vs. 0.15 ± 0.50 mm3/mm/year, P = 0.02) and a higher Δ plaque index (2.41 ± 2.53% vs. 0.69 ± 2.22%, P = 0.01). Patients with PED were more likely to experience MACE during a median follow-up of 8.2 years (interquartile range [7.6, 8.4]), after adjustment for potential cofounders such as age, high-density lipoprotein cholesterol levels, total rejection score, baseline International Society for Heart & Lung Transplantation CAV grade, and indication of transplantation. (hazard ratio 2.15, 95% confidence interval [1.09, 4.23], P = 0.03). Conclusions Peripheral endothelial dysfunction is associated with increased plaque progression and adverse long-term cardiovascular outcomes in transplant patients. PED assessment might be a useful clinical tool for risk stratification after heart transplantation.
Reply to the letter to the editor “Thiamine deficiency unrelated to alcohol consumption in high‐income countries: a literature review”
Gomes, Filomena , Bergeron, Gilles, Bourassa, Megan W. , Fischer, Philip R.

Mayo Clinic

Annals of the New York Academy of Sciences | September 12, 2021 | Volume: 1505 | Issue: 1 | Pages: 7-7

10.1111/nyas.14696 | PMID 34510473 Get It

What to do about the leaky gut
Camilleri, Michael , Vella, Adrian

Mayo Clinic

Gut | September 11, 2021 | Volume: 71 | Issue: 2 | Pages: 424-435

10.1136/gutjnl-2021-325428 | PMID 34509978 Get It

UK5099 inhibits macrophage activation independent of mitochondrial pyruvate carrier mediated metabolism
Ran, Linyu, Zhang, Song , Zhou, Jiaqi , Gan, Haiyun , Li, Qiang , Herrmann, Joerg , Zhang, Song , Ran, Linyu, Zhao, Pei , Jeon, Ryoung‐Hoon , Wang, Feilong

Mayo Clinic

No container title available | September 10, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-888198/v1 Get It

Abstract Glycolysis is essential for the classical activation of macrophages (M1), but how glycolytic pathway metabolites engage in this process remains to be elucidated. Glycolysis culminates in the production of pyruvate, which can be transported into the mitochondria by the mitochondrial pyruvate carrier (MPC) followed by conversion to citrate and utilization in the TCA cycle. Alternatively, pyruvate can be metabolized to lactate under aerobic conditions, which had been considered to be the dominant route in the setting of classical macrophage activation. However, based on studies that used UK5099 as a MPC inhibitor and showed reduction in key inflammatory cytokines, the mitochondrial route has been considered to be of significance for M1 activation as well. Herein, using a genetic depletion model, we found that MPC is dispensable for metabolic reprogramming and the activation of M1. While UK5099 reaches maximal MPC inhibitory capacity at approximately 2–5µM, higher concentrations are required to inhibit inflammatory cytokine production in M1 and this is independent of MPC expression. Apart from MPC inhibition, UK5099 at high doses impairs glutamate oxidation, mitochondrial membrane potential and HIF-1α stabilization. Taken together, UK5099 inhibits inflammatory responses in M1 macrophages due to effects other than MPC inhibition.
Review article: targeting the B cell activation system in autoimmune hepatitis
Czaja, Albert J.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 10, 2021 | Volume: 54 | Issue: 7 | Pages: 902-922

10.1111/apt.16574 | PMID 34506662 Get It

SummaryBackgroundThe B cell activation system, consisting of B cell activating factor and a proliferation‐inducing ligand, may have pathogenic effects in autoimmune hepatitis.AimsTo describe the biological actions of the B cell activation system, indicate its possible role in autoimmune diseases, and evaluate its prospects as a therapeutic target in autoimmune hepatitisMethodsEnglish abstracts were identified in PubMed by multiple search terms. Full length articles were selected for review, and secondary and tertiary bibliographies were developed.ResultsThe B cell activating factor is crucial for the maturation and survival of B cells, and it can co‐stimulate T cell activation, proliferation, and survival. It can also modulate the immune response by inducing interleukin 10 production by regulatory B cells. A proliferation‐inducing ligand modulates and diversifies the antibody response by inducing class‐switch recombination in B cells. It can also increase the proliferation, survival, and antigen activation of T cells. These immune stimulatory actions can be modulated by inducing proliferation of regulatory T cells. The B cell activation system has been implicated in diverse autoimmune diseases, and therapeutic blockade is a management strategy now being evaluated in autoimmune hepatitis.ConclusionsThe B cell activation system has profound effects on B and T cell function in autoimmune diseases. Blockade therapy is being actively evaluated in autoimmune hepatitis. Clarification of the critical pathogenic components of the B cell activation system will improve the targeting, efficacy, and safety of blockade therapy in this disease.
Clinical Profiles of Glaucomatous Patients With High-tension and Low-tension Optic Disc Hemorrhages: A Comparative Study
Almeida, Izabela N.F., Dias, Diego T., Alhadeff, Paula A., Lopes, Flavio S.S., Paranhos, Augusto, Ritch, Robert, Gracitelli, Carolina P.B., Prata, Tiago S., Almeida, Izabela N.F., Dias, Diego T., Alhadeff, Paula A., Lopes, Flavio S.S., Paranhos, Augusto, Ritch, Robert, Gracitelli, Carolina P.B., Prata, Tiago S.

Mayo Clinic

Journal of Glaucoma | September 10, 2021 | Volume: 31 | Issue: 3 | Pages: 178-182

10.1097/ijg.0000000000001937 | PMID 34506356 Get It

Précis: Patients with low-tension optic disc hemorrhages (DHs) are more frequently women, have a diagnosis of normal-tension glaucoma (NTG) diagnosis and greater visual field (VF) loss. Symptoms of vascular dysregulation and Asian race also seem to be more prevalent in this clinical subtype. Purpose: Optic DH is an important glaucoma risk factor, and occurs in a wide intraocular pressure (IOP) range. We sought to characterize distinct clinical subtypes of patients with high-tension disc hemorrhage (HTDH) and low-tension disc hemorrhage (LTDH). Patients and Methods: In this cross-sectional study, treated glaucomatous patients with DHs from 2 glaucoma services were consecutively enrolled. Disc photographs were evaluated for the presence of DH by 2 glaucoma specialists. After inclusion, patients were classified on HTDH (IOP≥16 mm Hg) and LTDH (IOP<16 mm Hg; median split). Clinical and ocular data from the time of DH detection were compared between groups. Results: One hundred thirty-three DH patients were included (LTDH=66 eyes; HTDH=67 eyes). Patients with LTDH were more often women than those with HTDH (77% vs. 42%; P =0.030). There was also a trend for a higher prevalence of Asian descendants (24% vs. 9%; P =0.058) and symptoms suggestive of vascular dysregulation (34% vs. 14%; P =0.057) in LTDH patients. Eyes with LTDH also had worse VF mean deviation index ( P =0.037), higher prevalence of NTG diagnosis (46% vs. 17%; P <0.001), and tended to have thinner central corneas ( P =0.066). Conclusions: Patients developing DHs with treated IOPs in the low teens seem to more frequently fit in a profile represented by women, NTG diagnosis and greater VF loss. The presence of symptoms suggestive of vascular dysregulation and race also seem to differ between these 2 clinical subtypes. A closer optic disc surveillance is recommended for patients with the LTDH subtype, as they may develop DHs despite seemingly well-controlled IOP.